Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapts (NQ: ACRS )

4.205 +0.245 (+6.19%)
Streaming Delayed Price Updated: 3:02 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aclaris Therapts

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
Aclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates. 
Via Benzinga
War, Gold, And Opportunity: Uncovering Today’s Market Moves
Geopolitical tensions drive market moves as we analyze top picks. 
Via Talk Markets
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Aclaris Therapeutics: Q4 Earnings Insights
Via Benzinga
The Analyst Landscape: 4 Takes On Aclaris Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. 
Via MarketBeat
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
Via Benzinga
$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024
ACRS stock results show that Aclaris Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END 
Via FinancialNewsMedia
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape. 
Via Benzinga
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the... 
Via Benzinga
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?
Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximately $182M in cash, cash equivalents, and marketable securities. Aclaris... 
Via Benzinga
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
Crude Oil Falls 1%; Amarin Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Wednesday. The Dow traded up 0.29% to 37,633.43 while the NASDAQ rose 0.72% to 14,965.31. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 50 points on Wednesday. The Dow traded up 0.17% to 37,588.15 while the NASDAQ rose 0.34% to 14,908.42. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial
Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
Dow Surges 100 Points; PriceSmart Earnings Top Views
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.27% to 37,627.83 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Inflammatory Disease Focused Aclaris Therapeutics Reduces Staff After Failed Psoriatic Arthritis Study
Aclaris Therapeutics Inc (NASDAQ: ACRS) announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed  
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.